dcterms.isReferencedBy |
Antuna-Puente, B., Feve, B., Fellahi, S., Bastard, J.-P., Adipokines: The missing link between insulin resistance and obesity (2008) Diabetes Metab., 34 (1), pp. 2-11; Bailey, S.D., Loredo-Osti, J.C., Lepage, P., Faith, J., Fontaine, J., Desbiens, K.M., Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population (2006) Diabetes, 55 (10), pp. 2896-2902; Bastard, J.P., Maachi, M., Lagathu, C., Kim, M.J., Caron, M., Vidal, H., Recent advances in the relationship between obesity, inflammation, and insulin resistance (2006) Eur. Cytokine Network, 17 (1), pp. 4-12. , 16613757; Bttcher, Y., Teupser, D., Enigk, B., Berndt, J., Klting, N., Schn, M.R., Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans (2006) J. Clin. Endocrinol. Metab., 91 (7), pp. 2725-2731; Chang, Y.-H., Chang, D.-M., Lin, K.-C., Shin, S.-J., Lee, Y.-J., Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A meta-analysis and systemic review (2011) Diabetes Metab. Res. Rev., 27 (6), pp. 515-527; Conneely, K.N., Silander, K., Scott, L.J., Mohlke, K.L., Lazaridis, K.N., Valle, T.T., Variation in the resistin gene is associated with obesity and insulin-related phenotypes in Finnish subjects (2004) Diabetologia, 47 (10), pp. 1782-1788; El-Mesallamy, H.O., Kassem, D.H., El-Demerdash, E., Amin, A.I., Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus (2011) Metabolism, 60 (1), pp. 63-70; El-Shal, A.S., Pasha, H.F., Rashad, N.M., Association of resistin gene polymorphisms with insulin resistance in Egyptian obese patients (2013) Gene, 515 (1), pp. 233-238; Emamgholipour, S., Hossein-Nezhad, A., Najmafsha, R.A., Rahmani, M., Larijani, B., Promoter resistin gene polymorphism in patients with type 2 diabetes and its influence on concerned metabolic phenotypes (2009) Iran. J. Diabetes Lipid Disord., 2009, pp. 8-Dec. , 150-156; Fain, J.N., Cheema, P.S., Bahouth, S.W., Lloyd Hiler, M., Resistin release by human adipose tissue explants in primary culture (2003) Biochem. Biophys. Res. Commun., 300 (3), pp. 674-678; Filippatos, T.D., Randeva, H.S., Derdemezis, C.S., Elisaf, M.S., Mikhailidis, D.P., Visfatin/PBEF and atherosclerosis-related diseases (2010) Curr. Vasc. Pharmacol., 8 (1), pp. 12-28; Filippatos, T.D., Tsimihodimos, V., Derdemezis, C.S., Gazi, I.F., Saougos, V., Mikhailidis, D.P., Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile (2013) Nutr. Metab. Cardiovasc. Dis., 23 (4), pp. 330-336; Fujinami, A., Obayashi, H., Ohta, K., Ichimura, T., Nishimura, M., Matsui, H., Enzyme-linked immunosorbent assay for circulating human resistin: Resistin concentrations in normal subjects and patients with type 2 diabetes (2004) Clin. Chim. Acta, 339 (12), pp. 57-63; Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Visfatin: A protein secreted by visceral fat that mimics the effects of insulin (2005) Science, 307 (5708), pp. 426-430; Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Retraction (2007) Science, 318 (5850), p. 565. , 17962537; Gligor, R., Zdremtan, D., Pilat, L., Matei, I., Ionescu-T�rgovi?te, C., Cr�nic, I., Correlation of visfatin with the lipidic metabolism in diabetic and obese patients (2012) Proc. Rom. Acad., Series B, 1, pp. 37-43; Goldstein, B.J., Insulin resistance as the core defect in type 2 diabetes mellitus (2002) Am. J. Cardiol., 90 (5 A), pp. 3g-10g; Grundy, S.M., Cleeman, J.I., Merz, C.N., Brewer, H.B., Jr., Clark, L.T., Hunninghake, D.B., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines (2004) J. Am. Coll. Cardiol., 44 (3), pp. 720-732; Gulcelik, N.E., Usman, A., Grlek, A., Role of adipocytokines in predicting the development of diabetes and its late complications (2009) Endocrine, 36 (3), pp. 397-403; Hajer, G.R., Van Haeften, T.W., Visseren, F.L., Adipose tissue dysfunction in obesity, diabetes, and vascular diseases (2008) Eur. Heart J., 29 (24), pp. 2959-2971; Hivert, M.F., Sullivan, L.M., Fox, C.S., Nathan, D.M., D'Agostino, R.B., Sr., Wilson, P.W., Meigs, J.B., Associations of adiponectin, resistin, and tumor necrosis factor-? with insulin resistance (2008) J. Clin. Endocrinol. Metab., 93 (8), pp. 3165-3172; Hivert, M.F., Manning, A.K., McAteer, J.B., Dupuis, J., Fox, C.S., Cupples, L.A., Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study (2009) Diabetes, 58 (3), pp. 750-756; Hussain, S., Asghar, M., Javed, Q., Resistin gene promoter region polymorphism and the risk of hypertrophic cardiomyopathy in patients (2010) Transl. Res., 155 (3), pp. 142-147; Jamaluddin, M.S., Weakley, S.M., Yao, Q., Chen, C., Resistin: Functional roles and therapeutic considerations for cardiovascular disease (2012) Br. J. Pharmacol., 165 (3), pp. 622-632; Johansson, L.M., Johansson, L.E., Ridderstrle, M., The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects (2008) Metabolism, 57 (11), pp. 1558-1562; Krner, A., Bttcher, Y., Enigk, B., Kiess, W., Stumvoll, M., Kovacs, P., Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children (2007) Metabolism, 56 (6), pp. 772-777; Leander, K., Gigante, B., Silveira, A., Vikstrom, M., Hamsten, A., Hogberg, J., NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction (2012) Clin. Chim. Acta, 413 (78), pp. 727-732; Lim, S., Koo, B.K., Cho, S.W., Kihara, S., Funahashi, T., Cho, Y.M., Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: The Korean atherosclerosis study (KAS): A 42-month prospective study (2008) Atherosclerosis, 196 (1), pp. 398-404; Luk, T., Malam, Z., Marshall, J.C., Pre-B cell colony-enhancing factor (PBEF)/visfatin: A novel mediator of innate immunity (2008) J. Leukocyte Biol., 83 (4), pp. 804-816; Ma, X., Warram, J.H., Trischitta, V., Doria, A., Genetic variants at the resistin locus and risk of type 2 diabetes in Caucasians (2002) J. Clin. Endocrinol. Metab., 87 (9), pp. 4407-4410; Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: Insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man (1985) Diabetologia, 28 (7), pp. 412-419; McTernan, P.G., Kusminski, C.M., Kumar, S., Resistin (2006) Curr. Opin. Lipidol., 17 (2), pp. 170-175; Menzaghi, C., Coco, A., Salvemini, L., Thompson, R., De Cosmo, S., Doria, A., Trischitta, V., Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians (2006) J. Clin. Endocrinol. Metab., 91 (7), pp. 2792-2795; Menzaghi, C., Bacci, S., Salvemini, L., Mendonca, C., Palladino, G., Fontana, A., Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes (2013) PloS ONE, 8 (6), p. 64729; Miyamoto, Y., Morisaki, H., Kokubo, Y., Yamanaka, I., Tomoike, H., Okayama, A., Resistin gene variations are associated with the metabolic syndrome in Japanese men (2009) Obes. Res. Clin. Pract., 3, pp. 65-74; Norata, G.D., Ongari, M., Garlaschelli, K., Raselli, S., Grigore, L., Catapano, A.L., Plasma resistin levels correlate with determinants of the metabolic syndrome (2007) Eur. J. Endocrinol., 156 (2), pp. 279-284; Osawa, H., Tabara, Y., Kawamoto, R., Ohashi, J., Ochi, M., Onuma, H., Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population (2007) Diabetes Care, 30 (6), pp. 1501-1506; Paschou, P., Kukuvitis, A., Yavropoulou, M.P., Dritsoula, A., Giapoutzidis, V., Anastasiou, O., Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population (2010) Cytokine, 51 (1), pp. 25-27; Romacho, T., S�nchez-Ferrer, C.F., Peir�, C., Visfatin/Nampt: An adipokine with cardiovascular impact (2013) Mediators Inflammation, 2013, p. 946427; Saddi-Rosa, P., Oliveira, C.S., Giuffrida, F.M., Reis, A.F., Visfatin, glucose metabolism and vascular disease: A review of evidence (2010) Diabetol. Metab. Syndr., 2, p. 21; Saddi-Rosa, P., Viana De Oliveira, C.S., Crispim, F., Giuffrida, F.M., De Lima, V.C., Vieira, J.G., Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects (2013) Cardiovasc. Diabetol., 12 (1), p. 119; Scherer, P.E., Adipose tissue: From lipid storage compartment to endocrine organ (2006) Diabetes, 55 (6), pp. 1537-1545; Shaw, J.E., Sicree, R.A., Zimmet, P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030 (2010) Diabetes Res. Clin. Pract., 87 (1), pp. 4-14; Soumaya, K., Molecular mechanisms of insulin resistance in diabetes (2012) Adv. Exp. Med. Biol., 771, pp. 240-251; Suriyaprom, K., Phonrat, B., Namjuntra, P., Chanchay, S., Tungtrongchitr, R., The +299(G>A) resistin gene polymorphism and susceptibility to type 2 diabetes in Thais (2009) J. Clin. Biochem. Nutr., 44 (1), pp. 104-110; Tang, N.-P., Wang, L.-S., Yang, L., Zhou, B., Gu, H.-J., Sun, Q.-M., A polymorphism in the resistin gene promoter and the risk of coronary artery disease in a Chinese population (2008) Clin. Endocrinol., 68 (1), pp. 82-87; Tokuyama, Y., Osawa, H., Ishizuka, T., Onuma, H., Matsui, K., Egashira, T., Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus (2007) Metabolism, 56 (5), pp. 693-698; Tsukahara, T., Nakashima, E., Watarai, A., Hamada, Y., Naruse, K., Kamiya, H., Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients (2009) Diabetes Res. Clin. Pract., 84 (2), pp. 179-186; Ukkola, O., Kunnari, A., Kesaniemi, Y.A., Genetic variants at the resistin locus are associated with the plasma resistin concentration and cardiovascular risk factors (2008) Regul. Peptides, 149 (13), pp. 56-59; Uslu, S., Kebapci, N., Kara, M., Bal, C., Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus (2012) Exp. Ther. Med., 4 (1), pp. 113-120; Wen, Y., Lu, P., Dai, L., Association between resistin gene -420 C/G polymorphism and the risk of type 2 diabetes mellitus: A meta-analysis (2013) Acta Diabetol., 50 (2), pp. 267-272; Xie, H., Tang, S.-Y., Luo, X.-H., Huang, J., Cui, R.-R., Yuan, L.-Q., Insulin-like effects of visfatin on human osteoblasts (2007) Calcif. Tissue Int., 80 (3), pp. 201-210; Xu, J.Y., Sham, P.C., Xu, A., Tso, A.W., Wat, N.M., Cheng, K.Y., Resistin gene polymorphisms and progression of glycaemia in southern Chinese: A 5-year prospective study (2007) Clin. Endocrinol., 66 (2), pp. 211-217; Yan, J.-J., Tang, N.-P., Tang, J.-J., Jia, E.-Z., Wang, M.-W., Wang, Q.-M., Genetic variant in visfatin gene promoter is associated with decreased risk of coronary artery disease in a Chinese population (2010) Clin. Chim. Acta, 411 (12), pp. 26-30; Zhang, L.Q., Heruth, D.P., Ye, S.Q., Nicotinamide phosphoribosyltransferase in human diseases (2011) J. Bioanal. Biomed., 3, pp. 13-25. , 22140607; Zhang, Y.-Y., Gottardo, L., Thompson, R., Powers, C., Nolan, D., Duffy, J., A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes (2006) Obesity, 14 (12), pp. 2119-2126 |
|